A recent meta-analysis of 69 clinical trials found the risk for ischemic optic neuropathy from GLP-1 therapy is too low to be ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk for clinically important kidney and cardiovascula ...
The holidays are a time known for feasting on delicious food, but that might not be possible for people taking weight-loss drugs.
Reports of pulmonary aspiration and difficulties in diagnosing gastrointestinal complications in the perioperative period have highlighted the need for clear clinical guidance to manage these patients ...
The use of GLP-1s is linked to improved inflammatory bowel disease outcomes in patients with concomitant inflammatory bowel ...
Some of what RFK Jr. says about obesity prevention isn't new. But after having coined the catchy MAHA acronym, it’s likely ...
The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. The ...
There’s no single GLP-1 diet plan you need to follow. If you’re taking — or thinking about taking — a GLP-1 medication like ...
Viking Therapeutics shows strong data with VK2735, a potential competitor to major drugs. Discover why VKTX stock is a ...
The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.
Research shows an average weight loss of just 5% could save an annual $153bn in medical fees and lost productivity.